Patents Represented by Attorney, Agent or Law Firm Wayne J. Dustman
  • Inhibitors of Akt activity
    Patent number: 8338434
    Abstract: Invented are novel pyrazole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: December 25, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark Andrew Seefeld, Meagan B. Rouse
  • Inhibitors of Akt activity
    Patent number: 8273782
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: September 25, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8088813
    Abstract: An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: January 3, 2012
    Assignee: GlaxoSmithKline LLC
    Inventor: Stephen Moore
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8071129
    Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: December 6, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis X Muller, Shivakumar G Kapsi
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8062665
    Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: November 22, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis X Muller, Shivakumar G Kapsi
  • 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8052995
    Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: November 8, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis X Muller, Shivakumar G Kapsi
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8052993
    Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: November 8, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis X Muller, Shivakumar G Kapsi
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8052994
    Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: November 8, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis X. Muller, Shivakumar G. Kapsi
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 7795293
    Abstract: An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: September 14, 2010
    Assignee: GlaxoSmithKline LLC
    Inventor: Stephen Moore
  • Thrombopoietin mimetics
    Patent number: 7790704
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: September 7, 2010
    Assignee: GlaxoSmithKline, LLC
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo
  • Chemical compounds
    Patent number: 7767701
    Abstract: This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: August 3, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Masaichi Hasegawa, Jun Tang, Hideyuki Sato
  • Thrombopoietin activity modulating compounds and methods
    Patent number: 7691895
    Abstract: Disclosed herein are compounds of Formula (I), (II), and (III) pharmaceutical compositions comprising the same, methods of modulating the activity a thrombopoietin receptor using the same, methods of identifying compounds as thrombopoietin receptor modulators, and methods of treating disease by administering a compound of the invention to a patient in need thereof.
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: April 6, 2010
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Jyun-Hung Chen, E. Adam Kallel, Thomas Lau, Matthew H. McNeill, Todd A. Miller, Bao N. Nguyen, Richard J. Penulian, Dean P. Phillips, Daniel A. Ruppar, Lin Zhi, Jackline E. Dalgard
  • Thrombopoietin mimetics
    Patent number: 7674887
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: March 9, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin J. Duffy, Juan I. Luengo, Antony N. Shaw, Kenneth Wiggall
  • 5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
    Patent number: 7674792
    Abstract: Invented is the compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6 -dichlorophenyl)amino]-1,3-thiazol-4(5H)-one, and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are pharmaceutical compositions containing this compound, methods of preparing this compound and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are methods of using this compound as an inhibitor of hYAK3 proteins.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: March 9, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin J. Duffy, Duke M. Fitch, Beth A. Norton
  • 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3?-(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
    Patent number: 7666857
    Abstract: An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3?-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: February 23, 2010
    Assignee: SmithKline Beecham Corp.
    Inventors: Christopher S. Brook, Li-Jen J. Ping
  • Thrombopoietin activity modulating compounds and methods
    Patent number: 7662804
    Abstract: Disclosed herein are novel diazenyl pyrazole compounds and related compounds. Also disclosed herein are methods of using these compounds for the treatment of diseases and conditions associated with modulating a thrombopoietin activity.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: February 16, 2010
    Assignee: SmithKline Beecham Corp.
    Inventors: Lin Zhi, E. Adam Kallel, Dean P. Phillips
  • Thrombopoietin mimetics
    Patent number: 7648971
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: January 19, 2010
    Assignee: SmithKline Beecham Corp.
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo, Sophie Visonneau
  • Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
    Patent number: 7625890
    Abstract: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: December 1, 2009
    Assignee: SmithKline Beecham Corp.
    Inventors: Dirk A. Heerding, Tammy J. Clark, Jack Dale Leber, Igor Safonov
  • 3?-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2?-hydroxy-[1,1?-piphenyl]-acid bis-(monoethanolamine)
    Patent number: 7547719
    Abstract: An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: June 16, 2009
    Assignee: SmithKline Beecham Corp.
    Inventor: Stephen Moore
  • Thrombopoietin mimetics
    Patent number: 7473686
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: January 6, 2009
    Assignee: SmithKline Beecham Corp.
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo, Sophie Visonneau